Regencell Bioscience Holdings LTD (RGC) — 20-F Filings
All 20-F filings from Regencell Bioscience Holdings LTD. Browse 2 Foreign Annual Report reports with AI-powered summaries and risk analysis.
20-F Filings (2)
-
Regencell Posts $3.58M Loss, Eyes ADHD/ASD TCM Approval
— Oct 31, 2025 Risk: high
Regencell Bioscience Holdings Ltd (RGC) reported net losses of $3.58 million for the fiscal year ended June 30, 2025, following a $4.36 million net loss in fisc -
Regencell Bioscience Files 2024 Annual Report
— Oct 25, 2024 Risk: low
Regencell Bioscience Holdings Ltd. filed its annual report on Form 20-F for the fiscal year ended June 30, 2024. The company, incorporated in the Cayman Islands
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX